Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability.

Rodrigues GA, Mason M, Christie LA, Hansen C, Hernandez LM, Burke J, Luhrs KA, Hohman TC.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5836-5846. doi: 10.1167/iovs.18-25307.

PMID:
30535424
2.

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.

Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, Cheetham JK, Hohman TC, Kim K, López FJ, Schneider S.

J Ocul Pharmacol Ther. 2018 Nov 9. doi: 10.1089/jop.2018.0062. [Epub ahead of print]

3.

Hereditary Retinal Dystrophy.

Hohman TC.

Handb Exp Pharmacol. 2017;242:337-367. doi: 10.1007/164_2016_91. Review.

PMID:
28035529
4.

Reticular drusen associated with geographic atrophy in age-related macular degeneration.

Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; Geographic Atrophy Progression (GAP) Study Group.

Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5009-15. doi: 10.1167/iovs.11-7235.

PMID:
21498612
5.

Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration.

Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, Hohman TC, Holz FG.

Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):1-6. doi: 10.1167/iovs.10-5619.

PMID:
20688734
6.

Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.

Hohman TC.

Retina. 2009 Jun;29(6 Suppl):S51-3. doi: 10.1097/IAE.0b013e3181ad23b5.

PMID:
19553804
7.

Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.

Berkowitz BA, Roberts R, Luan H, Peysakhov J, Knoerzer DL, Connor JR, Hohman TC.

Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2954-60.

PMID:
16043871
8.

Minalrestat and leukocyte migration in diabetes mellitus.

Cruz JW, Soto-Suazo MW, Hohman TC, Akamine EH, Zorn TT, Fortes ZB.

Diabetes Metab Res Rev. 2003 May-Jun;19(3):223-31.

PMID:
12789656
9.

Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes.

Akamine EH, Hohman TC, Nigro D, Carvalho MH, de Cássia Tostes R, Fortes ZB.

J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.

PMID:
12604701
10.

Molecular mechanism(s) of insulin action on the expression of the angiotensinogen gene in kidney proximal tubular cells.

Wu XH, Chen X, Zhang SL, Pang L, To C, Wang TT, Hohman TC, Filep JG, Chan JS.

J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):166-74.

PMID:
11967809
11.

Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.

Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C, Kokai Y.

Brain. 2001 Dec;124(Pt 12):2448-58.

PMID:
11701599
12.
13.
14.

ATP-sensitive K(+) channel effects on nerve function, Na(+), K(+) ATPase, and glutathione in diabetic rats.

Hohman TC, Cotter MA, Cameron NE.

Eur J Pharmacol. 2000 Jun 2;397(2-3):335-41.

PMID:
10844132
15.

Retinal capillary dilation: early diabetic-like retinopathy in the galactose-fed rat model.

Glover JP, Jacot JL, Basso MD, Hohman TC, Robison WG Jr.

J Ocul Pharmacol Ther. 2000 Apr;16(2):167-72.

PMID:
10803427
16.

Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.

Singh SB, Malamas MS, Hohman TC, Nilakantan R, Carper DA, Kitchen D.

J Med Chem. 2000 Mar 23;43(6):1062-70.

PMID:
10737739
17.

Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes.

Cruz JW, Oliveira MA, Hohman TC, Fortes ZB.

Eur J Pharmacol. 2000 Mar 10;391(1-2):163-74.

PMID:
10720648
18.

Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats.

Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC.

Diabetologia. 1999 Sep;42(9):1120-30.

PMID:
10447525
19.

Subnormal retinal oxygenation response precedes diabetic-like retinopathy.

Berkowitz BA, Kowluru RA, Frank RN, Kern TS, Hohman TC, Prakash M.

Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2100-5.

PMID:
10440266
20.

Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells.

Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS.

Kidney Int. 1999 Feb;55(2):454-64.

21.

Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.

Hohman TC, El-Kabbani O, Malamas MS, Lai K, Putilina T, McGowan MH, Wane YQ, Carper DA.

Eur J Biochem. 1998 Sep 1;256(2):310-6.

22.

Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.

Robison WG Jr, Jacot JL, Glover JP, Basso MD, Hohman TC.

Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1933-41.

PMID:
9727416
23.
24.
26.

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.

Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM.

Diabetes Care. 1996 Oct;19(10):1091-6.

PMID:
8886554
27.

Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.

Forster HG, ter Wee PM, Hohman TC, Epstein M.

Diabetologia. 1996 Aug;39(8):907-14.

PMID:
8858212
28.

Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509.

Robinson WG Jr, Laver NM, Jacot JL, Glover JP, Basso MD, Blouin P, Hohman TC.

Invest Ophthalmol Vis Sci. 1996 May;37(6):1149-56.

PMID:
8631629
31.

Aminoguanidine does not inhibit aldose reductase activity in galactose-fed rats.

Dvornik D, Hohman TC, Basso MD.

J Diabetes Complications. 1996 Jan-Feb;10(1):23-30.

PMID:
8639971
32.

Residues affecting the catalysis and inhibition of rat lens aldose reductase.

Carper DA, Hohman TC, Old SE.

Biochim Biophys Acta. 1995 Jan 5;1246(1):67-73.

PMID:
7811733
33.

Na,K-ATPase response to osmotic stress in primary dog lens epithelial cells.

Old SE, Carper DA, Hohman TC.

Invest Ophthalmol Vis Sci. 1995 Jan;36(1):88-94.

PMID:
7822162
34.

Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat.

Forster HG, ter Wee PM, Takenaka T, Hohman TC, Epstein M.

Proc Soc Exp Biol Med. 1994 Sep;206(4):365-74.

PMID:
8073045
35.

Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.

Kamijo M, Basso M, Cherian PV, Hohman TC, Sima AA.

Diabetes Res Clin Pract. 1994 Sep;25(2):117-29.

38.

Hydrolase compartmentalization limits rate of digestion in Acanthamoeba.

Hohman TC, Bowers B.

J Eukaryot Microbiol. 1993 Sep-Oct;40(5):589-93.

PMID:
8401472
39.

Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.

Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B.

J Diabetes Complications. 1993 Jul-Sep;7(3):157-69.

40.

Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.

Wrobel J, Dietrich A, Woolson SA, Millen J, McCaleb M, Harrison MC, Hohman TC, Sredy J, Sullivan D.

J Med Chem. 1992 Nov 27;35(24):4613-27.

PMID:
1469692
41.

Hypertonic stress induces alpha B-crystallin expression.

Dasgupta S, Hohman TC, Carper D.

Exp Eye Res. 1992 Mar;54(3):461-70.

PMID:
1381680
42.

Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.

McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG Jr.

Diabetologia. 1991 Oct;34(10):695-701.

PMID:
1959701
43.

Osmotic stress induces aldose reductase in glomerular endothelial cells.

Hohman TC, Carper D, Dasgupta S, Kaneko M.

Adv Exp Med Biol. 1991;284:139-52. No abstract available.

PMID:
1711272
44.

Induction of aldose reductase expression in rat kidney mesangial cells and Chinese hamster ovary cells under hypertonic conditions.

Kaneko M, Carper D, Nishimura C, Millen J, Bock M, Hohman TC.

Exp Cell Res. 1990 May;188(1):135-40.

PMID:
2109701
45.

Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.

Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH.

Invest Ophthalmol Vis Sci. 1989 Nov;30(11):2285-92.

PMID:
2509395
46.

Polyol and vacuole formation in cultured canine lens epithelial cells.

Nagata M, Hohman TC, Nishimura C, Drea CM, Oliver C, Robison WG Jr.

Exp Eye Res. 1989 May;48(5):667-77.

PMID:
2500357
47.

Aldose reductase and polyol in cultured pericytes of human retinal capillaries.

Hohman TC, Nishimura C, Robison WG Jr.

Exp Eye Res. 1989 Jan;48(1):55-60.

PMID:
2493386
48.

Purification of plasma membrane from Acanthamoeba castellanii.

Clarke BJ, Hohman TC, Bowers B.

J Protozool. 1988 Aug;35(3):408-13.

PMID:
3184000
49.

Characterization of mRNA and genes for aldose reductase in rat.

Nishimura C, Graham C, Hohman TC, Nagata M, Robison WG Jr, Carper D.

Biochem Biophys Res Commun. 1988 Jun 30;153(3):1051-9.

PMID:
3134017
50.

Relationship between proteins encoded by three human gamma-crystallin genes and distinct polypeptides in the eye lens.

Russell P, Meakin SO, Hohman TC, Tsui LC, Breitman ML.

Mol Cell Biol. 1987 Sep;7(9):3320-3.

Supplemental Content

Loading ...
Support Center